Key Highlights For The
Pharma Business

  • Delivered revenues of `4,786 Crore in FY2019, growing 11% y-o-y and contributing 36% to overall PEL revenue mix
  • Strong presence in regulated markets
  • Strong focus in the areas of quality, compliance and reliability helped consistent revenue growth since FY2011, despite challenging business environment
  • Global Pharma EBITDA grew at a CAGR of 24% over last 3 years
  • Global Pharma EBITDA margins at 23% in FY2019 as compared to 10% in FY2011
  • Margin expansion primarily driven by synergies from acquisitions, growth from high margin businesses, niche manufacturing capabilities, higher capacity utilisation, process optimisations, global distribution presence, cost improvement initiatives, and backward integration of raw material
  • Our differentiated business model has enabled us to perform better than most other Indian pharma companies
  • Over 90% of revenues derived from niche businesses of complex generics and Contract Development and Manufacturing Operations (CDMO), as compared with less than 5% for most large Indian Pharma companies
  • Built strong capabilities in High Potency Active Pharmaceutical Ingredients and Antibody Drug Conjugates
  • Positioned ourselves as partner of choice for large Global Pharma and virtual Biotech companies
  • Built niche capabilities in complex products such as injectable anesthesia, inhalation anesthesia, intrathecal spasticity etc.
  • Business seeing recovery post GST impact with H2 FY2019 revenues up 30% as compared to H1 FY2019
  • Tapping ecommerce, rural, exports and alternate opportunities in order to widen the distribution network
  • Using analytics for developing sales strategy and setting credit limits for distributors
  • Improving reach to match complete product availability and reducing stock-outs